Literature DB >> 17038690

Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).

Mark Reid1, Donna Mackenzie, Andrew Baron, Natalie Lehmann, Kym Lowry, John Aaskov, Farshad Guirakhoo, Thomas P Monath.   

Abstract

Australian mosquitoes from which Japanese encephalitis virus (JEV) has been recovered (Culex annulirostris, Culex gelidus, and Aedes vigilax) were assessed for their ability to be infected with the ChimeriVax-JE vaccine, with yellow fever vaccine virus 17D (YF 17D) from which the backbone of ChimeriVax-JE vaccine is derived and with JEV-Nakayama. None of the mosquitoes became infected after being fed orally with 6.1 log(10) plaque-forming units (PFU)/mL of ChimeriVax-JE vaccine, which is greater than the peak viremia in vaccinees (mean peak viremia = 4.8 PFU/mL, range = 0-30 PFU/mL of 0.9 days mean duration, range = 0-11 days). Some members of all three species of mosquito became infected when fed on JEV-Nakayama, but only Ae. vigilax was infected when fed on YF 17D. The results suggest that none of these three species of mosquito are likely to set up secondary cycles of transmission of ChimeriVax-JE in Australia after feeding on a viremic vaccinee.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038690

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  9 in total

1.  Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus.

Authors:  Justin R Darwin; Joan L Kenney; Scott C Weaver
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment.

Authors:  Thomas P Monath; Stephen J Seligman; James S Robertson; Bruno Guy; Edward B Hayes; Richard C Condit; Jean Louis Excler; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2014-10-27       Impact factor: 3.641

3.  Japanese Encephalitis Vaccines.

Authors:  Monica A McArthur; Michael R Holbrook
Journal:  J Bioterror Biodef       Date:  2011-09-25

Review 4.  Japanese encephalitis and vaccines: past and future prospects.

Authors:  Maria Paulke-Korinek; Herwig Kollaritsch
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

5.  Experimental infection of Aedes sollicitans and Aedes taeniorhynchus with two chimeric Sindbis/Eastern equine encephalitis virus vaccine candidates.

Authors:  Nicole C Arrigo; Douglas M Watts; Ilya Frolov; Scott C Weaver
Journal:  Am J Trop Med Hyg       Date:  2008-01       Impact factor: 2.345

6.  Dual miRNA targeting restricts host range and attenuates neurovirulence of flaviviruses.

Authors:  Konstantin A Tsetsarkin; Guangping Liu; Heather Kenney; Jose Bustos-Arriaga; Christopher T Hanson; Stephen S Whitehead; Alexander G Pletnev
Journal:  PLoS Pathog       Date:  2015-04-23       Impact factor: 6.823

Review 7.  Flavivirus-mosquito interactions.

Authors:  Yan-Jang S Huang; Stephen Higgs; Kate McElroy Horne; Dana L Vanlandingham
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

8.  European Aedes albopictus and Culex pipiens Are Competent Vectors for Japanese Encephalitis Virus.

Authors:  Mélissanne de Wispelaere; Philippe Desprès; Valérie Choumet
Journal:  PLoS Negl Trop Dis       Date:  2017-01-13

Review 9.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.